MARK PEDIGO: Open Payments
NPI 1144798570 · DENTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,336 in 195 payments from 36 companies in 2025. Trend: 2023 $3,120 · 2024 $2,066 · 2025 $3,336
Food & beverage: $3,336
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $356 |
| AstraZeneca Pharmaceuticals LP | 15 | $284 |
| Novo Nordisk Inc | 17 | $283 |
| Bayer Healthcare Pharmaceuticals Inc. | 19 | $257 |
| ABBVIE INC. | 19 | $246 |
| Novartis Pharmaceuticals Corporation | 8 | $199 |
| Lundbeck LLC | 13 | $181 |
| Lilly USA, LLC | 11 | $177 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $167 |
| GlaxoSmithKline, LLC. | 6 | $123 |
Products named: REXULTI, Kerendia, LEQVIO, Ozempic, FARXIGA, CAPLYTA, VRAYLAR, MOUNJARO.
Industry payments across TX — which companies pay providers there.
